Understanding how LITAF helps cells repair damage and fight inflammation
LITAF regulation of membrane repair and inflammation
This study is looking at how a protein called LITAF helps lung cells heal and reduce inflammation after they get damaged by infections or stress, which could lead to better treatments for conditions that cause lung inflammation.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Benaroya Research Inst at Virginia Mason NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11113889 on NIH RePORTER |
What this research studies
This research investigates the role of a protein called LITAF in helping cells repair their membranes after damage caused by infections or stress. The study aims to understand how LITAF is activated and how it contributes to reducing inflammation in the lungs, particularly in response to bacterial infections. By using advanced genetic screening techniques, researchers will identify the mechanisms through which LITAF protects cells from death and promotes healing. This could lead to new insights into treating inflammatory conditions and infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from lung inflammation or infections, particularly those caused by bacterial pathogens.
Not a fit: Patients with non-inflammatory conditions or those not affected by bacterial infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that enhance the body's ability to repair damaged cells and reduce inflammation, improving outcomes for patients with respiratory infections.
How similar studies have performed: Other research has shown promising results in understanding cellular repair mechanisms and their role in inflammation, suggesting that this approach could yield valuable insights.
Where this research is happening
Seattle, United States
- Benaroya Research Inst at Virginia Mason — Seattle, United States (Active)
Researchers
- Principal investigator: Lacy-Hulbert, Adam — Benaroya Research Inst at Virginia Mason
- Study coordinator: Lacy-Hulbert, Adam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.